The Borrelia burgdorferi BpaB proteins of the spirochete's ubiquitous cp32 prophages are DNA-binding proteins, required both for maintenance of the bacteriophage episomes and for transcriptional regulation of the cp32 erp operons. Through use of DNase I footprinting, we demonstrate that BpaB binds the erp operator initially at the sequence 5'-TTATA-3'. Electrophoretic mobility shift assays indicated that BpaB also binds with high affinity to sites located in the 5' noncoding regions of two additional cp32 genes. Characterization of the proteins encoded by those genes indicated that they are a single-stranded DNA-binding protein and a nuclease, which we named SsbP and NucP, respectively. Chromatin immunoprecipitation indicated that BpaB binds erp, ssbP, and nucP in live B. burgdorferi. A mutant bacterium that overexpressed BpaB produced significantly higher levels of ssbP and nucP transcript than did the wild-type parent.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415502 | PMC |
| http://dx.doi.org/10.1128/JB.00661-12 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo.
MAbs
October 2024
Department of Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, Shanghai, China.
Article Synopsis
- * Biparatopic antibodies (bpAbs) improve efficacy in HER2-positive patients by binding to two different sites on the HER2 antigen, which enhances specificity and promotes effective antigen clustering.
- * The designed bpAb, KJ015, shows high production yields, stability, and effectiveness comparable to existing therapies while revealing promising potential when combined with other treatments in mouse models.
Characterization of a novel format scFv×VHH single-chain biparatopic antibody against metal binding protein MtsA.
Protein Sci
June 2024
Department of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan.
Article Synopsis
- Biparatopic antibodies (bpAbs) are engineered to target multiple epitopes on the same antigen but designing them effectively is challenging due to the variety of formats and required optimizations.
- This study focused on creating a new single-chain bpAb format using different linkers to connect specific antibody fragments that target the metal-binding protein MtsA.
- The research revealed that the length of the linker influences the assembly of the antibody complexes, with longer linkers resulting in more compact structures, offering valuable insights for future bpAb design.
Biparatopic antibodies: therapeutic applications and prospects.
MAbs
March 2024
Biologics, Mythic Therapeutics, Waltham, MA, USA.
Biparatopic antibodies (bpAbs) bind distinct, non-overlapping epitopes on an antigen. This unique binding mode enables new mechanisms of action beyond monospecific and bispecific antibodies (bsAbs) that can make bpAbs effective therapeutics for various indications, including oncology and infectious diseases. Biparatopic binding can lead to superior affinity and specificity, promote antagonism, lock target conformation, and result in higher-order target clustering.
View Article and Find Full Text PDFDevelopment of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection.
Commun Biol
September 2023
Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka, 562-0011, Japan.
Conventional bivalent antibodies against cell surface receptors often initiate unwanted signal transduction by crosslinking two antigen molecules. Biparatopic antibodies (BpAbs) bind to two different epitopes on the same antigen, thus altering crosslinking ability. In this study, we develop BpAbs against tumor necrosis factor receptor 2 (TNFR2), which is an attractive immune checkpoint target.
View Article and Find Full Text PDFExpeditious Generation of Biparatopic Common Light Chain Antibodies Chicken Immunization and Yeast Display Screening.
Front Immunol
June 2021
Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany.
Bispecific (BsAb) and biparatopic (BpAb) antibodies emerged as promising formats for therapeutic biologics exhibiting tailor-made functional properties. Over recent years, chicken-derived antibodies have gained traction for diagnostic and therapeutic applications due to their broad epitope coverage and convenience of library generation. Here we report the first generation of a biparatopic common light chain (cLC) chicken-derived antibody by an epitope binning-based screening approach using yeast surface display.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!